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Patients requiring liver transplantation (LT) frequently experience renal insuﬃciency (RI), which aﬀects their survival. Although
calcineurin inhibitor-sparing immunosuppressive regimens (CSRs) are well known to prevent RI, the immune state in recipients
receiving CSR remains to be intensively investigated. Among 60 cases of living-donor LT at our institute, 68% of the patients
had none to mild RI (non-RI group) and 32% of the patients had moderate to severe RI (RI group). The RI group received a
CSR comprising reduced dose of tacrolimus, methylprednisolone, and mycophenolate mofetil, while the non-RI group received a
regimen comprising conventional dose of tacrolimus and methylprednisolone. One year after LT, the mean estimated glomerular
ﬁltration rate (eGFR) in the RI group had signiﬁcantly improved, although it was still lower than that of the non-RI group. Serial
mixed lymphocyte reaction assays revealed that antidonor T-cell responses were adequately suppressed in both groups. Thus,
we provide evidence that CSR leads to improvement of eGFR after LT in patients with RI, while maintaining an appropriate
immunosuppressive state.
1.Introduction
Renal insuﬃciency (RI) has been widely recognized as a
serious complication of liver transplantation that signiﬁ-
cantly compromises patient outcome [1–4]. Since a number
of patients already have varying degrees of RI, including
hepatorenal syndrome, before undergoing liver transplanta-
tion, and since postoperative standard immunosuppression
protocols based on calcineurin inhibitors (CNIs) can lead to
severe tubular atrophy, interstitial ﬁbrosis, and focal hyali-
nosis of the small renal arteries and arterioles, a majority of
liver recipients develop some degree of RI [5–7]. An analysis
of data from the Scientiﬁc Registry of Transplant Recipients
indicates that the cumulative incidence of stage 4 [estimated
glomerular ﬁltration rate (eGFR)<30mL/min/1.73m2]o r
stage 5 chronic kidney disease (eGFR<15mL/min/1.73m2
or need for renal replacement therapy) after liver transplan-
tation is 18% at 5 years [8].
Late renal failure is associated with both pre- and
posttransplant factors, including higher concentrations of
CNIs both early and late posttransplant and can be predicted
by creatinine levels in the ﬁrst year posttransplant [9,
10]. The recognition of these eﬀects induced interest in
strategies using a CNI-sparing immunosuppressive regimen
(CSR). Current strategies to overcome CNI toxicity include
reduction or withdrawal of CNIs concurrent with switching
over to less nephrotoxic drugs like the mammalian target
of rapamycin (mTOR) inhibitor or mycophenolate mofetil
(MMF) [11–17]. Although these strategies have clearly
demonstrated the ability to reduce the incidence of nephro-
toxicity in various studies, CSR may result in an increased
risk for acute rejection episodes in a subset of patients.
In the present study, we investigated the immune state
in liver transplant patients suﬀering from RI who received a
CSRcomprisingareduceddoseofCNI,methylprednisolone,
and MMF. For monitoring the immune-state response to2 Journal of Transplantation
antidonor allostimulation in these patients, we employed a
mixed lymphocyte reaction (MLR) assay using an intracellu-
lar carboxyﬂuorescein diacetate succinimidyl ester (CFSE)-
labeling technique. By applying the CFSE-based method, the
proliferation of viable CD4+ and CD8+ responder T-cells in
response to allostimulation could be separately quantiﬁed
using multiparameter ﬂow cytometry [18]. The technique
allowed us to ﬁnd that antidonor T-cell responses were
adequately suppressed in patients with RI who received the
CSR and in patients without RI who received a conventional
immunosuppressive regimen.
2. Patientsand Methods
2.1. Patients. Between January 2003 and December 2009,
122 patients underwent living-donor LTs at Hiroshima
University Hospital. Of these, 50 patients infected with
hepatitis C virus (HCV) and 12 patients who received liver
allografts from ABO-blood group incompatible donors were
excluded from the study, because they were treated with
the diverse immunosuppressive protocols. For the remaining
60 patients, the relationship between RI prior to LT and
the clinical/immunological state after LT was investigated.
The following information was collected at the time of
the transplant: age, sex, etiology of liver disease, model
for end-stage liver disease (MELD) score, and diagnosis of
hepatocellular carcinoma (HCC) prior to LT. Renal function
was evaluated in each participant by determining eGFR.
The eGFR of each participant was calculated from their
serum creatinine value (SCr) and their age by using the new
Japanese equation [19] as follows:
eGFR

mL/min/1.73m2
= 194 ×Age − 0.287
×S −Cr −1.094 (if female ×0.739).
(1)
In this study, RI was deﬁned as none to mild (eGFR≥
60mL/min/1.73m2)andmoderate(30–59mL/min/1.73m2)
to severe (<30mL/min/1.73m2). The MELD score was
calculated for each patient using the United Network for
Organ Sharing (UNOS) formula based on the laboratory
values obtained just prior to LT. Patients were monitored for
renal function using serum creatinine level and eGFR at 1, 3,
6, and 12 months after LT.
2.2. Immunosuppressive Protocol. The basic immunosup-
pressive regimen after LT for the non-RI group comprised
tacrolimus (TAC) and methylprednisolone, with gradual
tapering of doses. Patients with RI received a CSR com-
prising a reduced dose of TAC, methylprednisolone, and
MMF (Figure 1). In the conventional regimen, the trough
whole blood levels of TAC were maintained between 8 and
15ng/mL in the ﬁrst few postoperative weeks and between 5
and 10ng/mL thereafter. In the CSR, the trough whole blood
levels of TAC were maintained between 5 and 10ng/mL in
the ﬁrst few postoperative weeks and between 3 and 5ng/mL
thereafter.
2 weeks 2∼3 months
TAC
MPL
Trough level 8∼15 5∼10 3∼8 (ng/mL)
After LT
(a) Conventional regimen
3∼5 0∼5
500∼1000
MMF
TAC
MPL
Trough level
2w e e k s 2∼3 months
5∼10 (ng/mL)
After LT
(b) CNI-sparing immunosuppressive regimen
Figure 1: Immunosuppressive protocol after liver transplanta-
tion. The basic immunosuppressive regimen comprised tacrolimus
(TAC) and methylprednisolone (MPL), with doses gradually being
tapered oﬀ. The trough whole blood levels of TAC were maintained
between 8 and 15ng/mL in the ﬁrst few postoperative weeks and
between 5 and 10ng/mL thereafter (a). Renal insuﬃciency (RI)
group received CNI-sparing immunosuppressive regimen (CSR)
consisting of TAC reduction and concomitant use of mycophenolat
mofetil (MMF) (b).
2.3. Immune Monitoring by an In Vitro MLR Assay. For
monitoring the immune state, an in vitro MLR assay was
performed at 1, 3, 6, and 12 months after LT. Brieﬂy,
peripheral blood mononuclear cells prepared from the blood
of the recipients, donors, and healthy volunteers with the
same blood type as the donors (third-party control) for use
as the stimulator cells were irradiated with 30 Gy, and those
obtained from the recipients for use as responder cells were
labeled with 5 lm CFSE (Molecular Probes Inc., Eugene,
OR, USA), as described previously [18]. The stimulator
and responder cells were incubated for 5 days. CFSE stably
stains intracellular proteins without causing toxicity, and the
ﬂuorescence intensity of each stained cell segregates equally
among daughter cells during cell division, resulting in
sequential halving of the cellular ﬂuorescence intensity with
every successive generation. After culturing for MLR, the
harvested cells were stained with either phycoerythrin- (PE-)
conjugated antihuman CD4 or PE-conjugated antihuman
CD8monoclonalantibodiesandsubjectedtoanalysisbyﬂow
cytometry. All analyses were performed on a FACSCalibur
ﬂow cytometer (Becton Dickinson, Mountain View, CA,
USA).T-cellproliferationwasvisualizedbytheserial-halving
of the ﬂuorescence intensity of CFSE. CD4+ and CD8+ T-cell
proliferation and stimulation index were quantiﬁed using a
method described previously [18].
2.4. Statistical Analysis. Quantitative variables were ex-
pressed as mean ± standard deviation (SD) or median
(range). Categorical variables were presented as values andJournal of Transplantation 3
Table 1: Patient characteristics at living donor liver transplantation.
Non-RI group (n = 41) RI group (n = 19) P value
(eGFR (mL/min/1.73 m2)) (94.8 ± 26.9) (42.5 ± 15.9)
Age at LT (years) 49.2 ± 11.5 52.9 ± 9.0 0.23
Male sex—n (%) 21 (51.2) 13 (68.4) 0.21
Primary diagnosis—n (%) 0.63
HBV 15 (36.6) 9 (47.4)
Alcoholic 8 (19.5) 5 (26.3)
AIH 4 (9.8) 1 (5.3)
Others 14 (34.1) 4 (21.1)
MELD 16.5 ± 7.1 24.7 ± 10.7 <0.01
eGFR at 1st year after LT (mL/min/1.73 m2) 77.2 ± 28.2 60.1 ± 13.5 <0.01
eGFR > 60 at 1st year after LT—n (%) 26 (72.2) 10 (58.8) 0.33
AR within 1st year—n (%) 10 (24.4) 5 (26.3) 0.87
Bacterial infections—n (%) 13 (31.7) 8 (42.1) 0.43
Fungal infections—n (%) 4 (9.8) 4 (21.1) 0.23
CMV infections—n (%) 10 (24.4) 7 (36.8) 0.32
RI, renal insuﬃciency; LT, liver transplantation; HBV, hepatitis B virus; AIH, Autoimmune hepatitis; eGFR, estimated glomerular ﬁltration rate; MELD,
model for end-stage liver disease; AR, acute rejection; CMV, cytomegalovirus. Data are expressed as means ± standard deviation. Diﬀerence with P<0.05
was considered signiﬁcant.
percentages. Student’s t-test, Mann-Whitney test, chi-square
test, and Fischer’s exact test were used to compare variables
between the two groups. Paired t-tests were performed to
compare continuous variables throughout the study period.
The Kaplan-Meier analyses were used to compare time-to-
event variables. P Values <0.05 were considered statistically
signiﬁcant.
3. Results
The 60 patients included 34 males and 26 females; their
ages ranged from 20 to 69 (median 52) years. The primary
diseases in these patients included hepatitis B virus-related
cirrhosis in 24 patients (of these, 18 patients had HCC),
alcoholic cirrhosis in 13 patients (of these, 6 patients had
HCC),autoimmunehepatitisin5patients(ofthese,1patient
had HCC), and other diseases in 18 patients.
Before the LTs, 68% of the patients had none to mild RI
(non-RI group; mean eGFR, 94.8 ± 26.9mL/min/1.73m2)
and 32% of the patients had moderate to severe RI (RI
group; mean eGFR, 42.5 ± 15.9mL/min/1.73m2). The char-
acteristics of these patients are listed in Table 1. There was
ad i ﬀerence in MELD score between the groups. Mean TAC
trough levels during the ﬁrst year after LT in the non-RI and
RIgroupsareshowninFigure 2(a). There were diﬀerencesin
m e a nT A Ct r o u g hl e v e l sd u r i n g3m o n t h sa f t e rL Tb e t w e e n
the groups. One year after the LDLTs, the mean eGFR in the
non-RI group had signiﬁcantly deteriorated (from 94.8 ±
26.9 to 77.2 ± 28.2mL/min/1.73m2, P<0.01). In contrast,
the mean eGFR in the RI group had signiﬁcantly improved
after LT (from 42.5 ± 15.9 to 60.1 ± 13.5mL/min/1.73m2,
P<0.01), although it was still lower than that of the non-RI
group (Figure 2(b)). Notably, 53% of the patients in the RI
group were completely cured of RI by 1 year after LT. None
of the patients had severe RI at 1 year after LT nor required
chronic hemodialysis during the observation period.
To evaluate the immune status of these patients,
we employed a serial MLR assay using a CFSE-labeling
technique. Lack of proliferation of both CD4+ and
CD8+ T-cells in the antidonor CFSE-MLR assay indicates
suppressionoftheantidonorresponse,whereasaremarkable
proliferation of these T-cells reﬂects a strong antidonor
response. In both groups, limited CD4+ and CD8+ T-cell
proliferation was observed in the antidonor responses as
compared with the anti-third-party responses through the
ﬁrst year. At 1 month after LT, the average of stimulation
index (SI) for CD4+ T-cells in response to anti-third-party
stimulation was >2 (the average value in healthy volunteers
without any immunosuppressive treatment) that is, there
was a normal response in the anti-third-party (Figures
3(a) and 3(b)). At 1 year after LT, the average of SIs for
CD4+ and CD8+ T-cells in response to both antidonor and
anti-third-party stimulation was <2 (Figures 3(c) and 3(d)).
There were no signiﬁcant diﬀerences in acute rejection rates,
bacterial, fungal, or cytomegalovirus infection rates and
patient survival between the groups (Table 1).
4. Discussion
Chronic RI is a serious complication in liver transplantation
thatsigniﬁcantlycompromisespatientsurvivalandoutcome.
Depending on the criteria applied for a deﬁnition of chronic
renalinsuﬃciencyandthedurationoffollowup,thereported
rate of chronic renal insuﬃciency after liver transplantation
may vary from 10% to 80% [1, 20–22]. CNI toxicity has
been deﬁned as one of the possible risk factors for renal
insuﬃciency in long-term liver transplant survivors. It has
been shown that exposure to CNIs within the ﬁrst 6 months4 Journal of Transplantation
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Figure 2: Kinetics of mean trough levels of tacrolimus and mean
estimated glomerular ﬁltration rate (eGFR) in the RI group and
non-RI group during the ﬁrst year after transplantation. (a) Mean
trough levels of tacrolimus in the non-RI group (black line) and
RI group (gray line). (b) Mean estimated glomerular ﬁltration rate
(eGFR) in the non-RI group (black line) and RI group (gray line).
Data are median ± SD of values. ∗P<0.05.
after liver transplantation represents a risk factor for renal
failure [23]. The GFR at 1 year had a better correlation with
later renal function than the pretransplant GFR [24]. The
recognition of these facts induced interest in preventing CNI
toxicity. It has also reported that the use of adjunctive MMF
immediately after LT might protect against CNI nephro-
toxicity, potentially without the need for dose reduction
or increased risk of adverse events [25]. Therefore, current
strategies to overcome CNI toxicity include reduction or
withdrawal of CNIs along with switching to mTOR inhibitor
or MMF-based regimens [11, 12, 14, 15, 26–28]. These
strategies have been documented in several recent and
ongoing trials to achieve an improvement in renal function
in a large proportion of liver transplant patients.
In our CSR using MMF, wherein our study results
agree with the results from previous studies, patients with
pre-transplant renal insuﬃciency were associated with less
impairmentofrenalfunctionwithoutanincreasedfrequency
of rejection, infection, or patient survival. In addition to
this clinical evidence for the usefulness of the CSR using
MMF, the present study provides immunological evidence,
by analyzing the data obtained from an MLR assay, that
antidonor T-cell responses were adequately suppressed in
patients who received the CSR and in patients who received
the conventional immunosuppressive regimen. Notably, the
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Figure 3: Kinetics of stimulation index in the RI group and non-
RI group during the ﬁrst year after transplantation. Stimulation
index (SI) of each of the CD4+ T-cell (a, b) and CD8+ T-cell (c,
d) subsets in the antidonor (a, c) and anti-third-party (b, d) MLR
in patients in non-RI group (black line) and RI group (gray line).
CD4+ andCD8+ T-cellproliferationandtheirSIswerequantiﬁedas
follows. The number of division precursors was extrapolated from
the number of daughter cells of each division, and the number of
mitotic events in each of the CD4+ and CD8+ T-cell subsets was
calculated. Using these values, the mitotic index was calculated by
dividing the total number of mitotic events by the total number of
precursors. The SIs of allogeneic combinations were calculated by
dividing the mitotic index of a particular allogeneic combination
by that of the self-control. The box plot represents the 25th to
75th percentile, the dark line is the median, and the extended bars
represent the 10th to the 90th percentile.
individual variations of SIs of CD4+ T-cell and CD8+ T-
cell subsets on antidonor T-cell responses in patients who
received the CSR were smaller than those in patients whoJournal of Transplantation 5
received the conventional regimen, although the average
values of both were similar. This might be explained by the
possibility that the CSR comprising triple immunosuppres-
sive drugs was equally eﬀective in a wide variety of patients.
Several limitations of this study are present. Our sample
size was relatively small without long-term followup, and
single-center retrospective data are reported. Since the 2
groups of patients are not perfectly comparable as renal
impairment can reduce immune responses, we could not
rule out a possibility that reduced CNI, without necessarily
adding MMF, may be suﬃcient for the treatment of these
patients.
We excluded HCV positive cases and ABO-blood group
incompatible cases from the study because of diverse proto-
col (In brief, in patients with HCV infection, methylpred-
nisolone is not administered, which may be beneﬁcial for
preventing enhanced viral replication. Instead, basiliximab
andMMFareusuallyadministeredtosuchpatients.InABO-
blood group incompatible cases, anti-CD20 monoclonal
antibody is administered for eliminating temporarily B
cells 2 weeks before transplantation, and simultaneously
commencing administration of CNI and MMF.). Hence, the
eﬀect of CSR in RI patients with those backgrounds remains
to be elucidated. Nevertheless, this ﬁrst evaluation of the
immune state in liver transplant patients suﬀering from RI
received a CSR was essential before to propose an evaluation
at a larger scale.
In conclusion, patients with pre-transplant RI receiving
CSR under immunological monitoring using an MLR assay
were associated with less impairment of renal function
without an increased frequency of rejection or patient
survival. Antidonor T-cell responses were adequately sup-
pressed in these patients as well as in patients who received
the conventional immunosuppressive regimen comprising a
standard dose of CNI.
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